U.S. Chemicals Stock News

How Balchem’s Recent Performance Frames the Story for Investors Balchem (BCPC) has been steady over the past day, but the stock is up about 1.4% over the past week and down roughly 7% over the past month, prompting closer investor attention. See our latest analysis for Balchem. That recent 7% one month share price pullback, alongside a 5.0% year to date share price gain and a 3 year total shareholder return of 34.3%, suggests momentum has cooled but long term holders have still been...

Recent share performance and context Oppenheimer Holdings (OPY) has seen mixed share performance recently, with the stock down about 3% over the past day and roughly 9% over the past month, yet up around 9% in the past 3 months. See our latest analysis for Oppenheimer Holdings. Despite the recent 9% decline in the 1 month share price return to US$93.86, momentum over the year still looks constructive. A 29.21% year to date share price return and a 50.07% 1 year total shareholder return...

In May 2026, MicroVision, Inc. reported first quarter 2026 results, with sales rising to US$935,000 from US$589,000 a year earlier, while net loss narrowed to US$25.29 million and basic loss per share improved to US$0.08 from US$0.12. This combination of higher sales and a smaller loss suggests incremental progress in MicroVision’s efforts to scale its lidar and perception technology business. We'll examine how this early revenue growth and reduced quarterly loss could influence...

Melco Resorts & Entertainment (MLCO) has been drawing attention after a period of weaker share performance, with the stock down over the past month and past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for Melco Resorts & Entertainment. At a latest share price of $5.38, Melco Resorts & Entertainment has seen its 7 day share price return fall 2.71% and its year to date share price return decline 28.36%, while the 5 year total shareholder return...

Why Post Holdings stock is on investors’ radar today Post Holdings (POST) is drawing attention after recent trading left the stock down over the past month and past 3 months, prompting investors to reassess its consumer packaged foods and foodservice footprint. At a recent close of US$97.17 and a market value of about US$4.4b, the company sits in the mid cap range for U.S. food and beverage stocks, with operations spanning cereals, pet food, refrigerated retail products, and foodservice...

Mirum Pharmaceuticals (MIRM) has just completed a zero coupon convertible note offering of $600 million due 2032, a financing move that can reshape its capital structure and influence how investors assess the stock. See our latest analysis for Mirum Pharmaceuticals. Mirum’s recent zero coupon convertible note offering comes after a mixed stretch for the stock, with the share price up 26.32% year to date but down 8.24% over 90 days. The one year total shareholder return of 124.14% and five...

Builders FirstSource previously filed a US$41.62 million shelf registration for 6,050,000 common shares tied to its ESOP and confirmed a planned leadership transition naming Mike Hiller as Chief Operating Officer-designate while appointing Coley O’Brien as Chief Human Resources Officer. This combination of an employee-focused share offering and a long-term succession plan underscores the company’s emphasis on workforce alignment and operational continuity. We’ll now examine how the COO...

Hub Group (HUBG) recently received a Nasdaq notice of non compliance after missing the filing deadline for its March 31, 2026 Form 10 Q, highlighting ongoing restatements and extended reporting uncertainty. See our latest analysis for Hub Group. The Nasdaq notice comes after Hub Group signaled delayed filings earlier in May, yet the stock has held relatively firm, with a 1-day share price return of 1.92%, a 7-day share price return of 8.62%, and a 1-year total shareholder return of 26.17%...

Event overview and recent share performance Open Text (NasdaqGS:OTEX) has drawn fresh attention after a period in which the stock is down about 26% year to date and down about 38% over the past 3 years, prompting investors to reassess the business. See our latest analysis for Open Text. Recent price action has been choppy, with a 1 month share price return of 4.73%, a year to date share price return that is down 26.06%, and a 3 year total shareholder return that is down 37.97%, signaling that...

Earlier this month, Driftwood Hospitality Management expanded its use of Flywire’s hospitality payments platform across nearly 90 U.S. hotel properties, digitizing contracts, deposits and multi-channel guest payments while cutting manual processing and fees, particularly through greater ACH adoption. This rollout shows how Flywire’s software-led payments model can reshape operational workflows for large hotel portfolios, pairing cost savings with a more seamless guest experience across major...

In May 2026, Inhibrx Biosciences reported a first-quarter net loss of US$33.44 million, narrower than a year earlier, and released positive interim Phase 2 data from its HexAgon trial of INBRX-106 plus pembrolizumab in first-line PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma. The interim data showed a higher confirmed objective response rate and the emergence of complete responses with the INBRX-106 combination, underscoring the potential...

Science Applications International (SAIC) has drawn fresh attention after its recent share performance, with the stock near US$100 and returns over the past 3 months outpacing its move over the past month. See our latest analysis for Science Applications International. At around US$100, the recent 3.99% 1 day and 14.19% 3 month share price returns suggest momentum has picked up again, even as the year to date share price return is slightly down and the 1 year total shareholder return has...

Recent stock move puts Old National Bancorp in focus Old National Bancorp (ONB) is back on investors’ radar after a recent share price move, with the stock last closing at US$23.94 and posting mixed short term returns across the past week and month. See our latest analysis for Old National Bancorp. That recent share price move sits within a steady trend, with a 1-year total shareholder return of 19.13% and a 3-year total shareholder return above 2x, suggesting momentum has been building over...

What Invitation Homes Stock Investors Are Watching Now Invitation Homes (INVH) has drawn attention after recent trading, with the stock last closing at $29.29. Investors are weighing this price against the company’s cash flow profile and recent share performance. See our latest analysis for Invitation Homes. Recent trading has added to a steady short term upswing, with a 30 day share price return of 7.96% and a 90 day share price return of 14.10%. However, the 1 year total shareholder return...

Meta Platforms stock performance snapshot Meta Platforms (META) has seen mixed share performance recently, with the stock up about 0.5% over the past day, slightly lower over the past week, and down over the past month and past 3 months. See our latest analysis for Meta Platforms. With the share price at US$610.26, Meta Platforms has recently pulled back, with the 30 day share price return down 9.6% and the year to date share price return down 6.2%. However, the 3 year total shareholder...

Insmed (INSM) is back in focus after recent trading pulled the stock down about 21% over the past month and roughly 33% over the past 3 months, prompting fresh attention on its rare disease portfolio. See our latest analysis for Insmed. At a share price of US$106.24, Insmed has seen short term momentum fade, with the 30 day share price return down 21.4% and the year to date share price return down 40%, even though the 1 year total shareholder return is 57.3% and the 3 year total shareholder...

Why CVS Health is on investors’ radar now CVS Health (CVS) is drawing fresh attention after its stock moved around current levels near US$93, with returns over the past month and past 3 months contrasting with a weaker recent week. See our latest analysis for CVS Health. At a share price of US$93.26, CVS Health has seen its short term share price momentum cool in the past week, even after strong 1 month and year to date share price returns and solid multi year total shareholder returns. If...

Walmart Inc. ( NASDAQ:WMT ) shareholders are probably feeling a little disappointed, since its shares fell 9.8% to...

It looks like CSX Corporation ( NASDAQ:CSX ) is about to go ex-dividend in the next three days. The ex-dividend date is...

It looks like The Estée Lauder Companies Inc. ( NYSE:EL ) is about to go ex-dividend in the next 3 days. The...

Shareholders in MasterCraft Boat Holdings, Inc. ( NASDAQ:MCFT ) may be thrilled to learn that the analysts have just...

In May 2026, Spire Global expanded its Cirrus platform with a full-stack weather forecasting suite for energy traders and was chosen by Amadeus IT Group to supply fused ground and space-based ADS-B data for its Virtual Airport Operations Center. This combination of advanced energy trading intelligence and a high-profile aviation data partnership highlights how Spire is pushing its satellite data into more operational, decision-critical workflows. Next, we’ll examine how the expanded Cirrus...

Recent performance snapshot Sensient Technologies (SXT) has drawn attention after a mixed stretch in its share performance, with the stock down about 7% over the past month but up roughly 20% over the past 3 months. See our latest analysis for Sensient Technologies. At a share price of $114.44, Sensient Technologies has posted a 22.47% year to date share price return and a 23.77% 1 year total shareholder return, suggesting recent momentum has strengthened against an already solid multi year...

In May 2026, Precigen, Inc. reported first-quarter 2026 results showing revenue of US$23.25 million versus US$1.34 million a year earlier, with net loss narrowing to US$7.93 million from US$54.15 million and basic loss per share from continuing operations improving to US$0.02 from US$0.18. The results highlighted how the launch of PAPZIMEOS and continued development of PRGN-2009 in HPV-associated cancers are reshaping Precigen’s financial profile and therapeutic focus. We’ll now examine how...